Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 26, 1203–1204 (1 November 2008) | doi:10.1038/nbt1108-1203
FDA cracks down on labeling, initiates trial result reporting
&
Abstract
One year after President George W. Bush signed the US Food and Drug Administration Amendments Act (FDAAA), industry watchers remain uncertain whether the new arsenal of post-market powers has added benefit or bureaucracy, but the provisions on labeling and post-marketing oversight are certainly being felt. In September, in line with the FDAAA, the US National Institutes of Health's publicly available database (http://www.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
